GlassScriptPhysician profile
Lu Hine
NPI 1790383446
$5,057.74
in general payments reported to CMS, 2019-2025
26 companies · $1,775 in 2025
The $1,775 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.31 · 2022: $555 · 2023: $1,193 · 2024: $1,519 · 2025: $1,775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,287 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,286.58 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,047.82 | 2021-2025 | Tremfya |
| Amgen INC. | $795.42 | 2022-2025 | Tavneos, Enbrel, Evenity |
| Abbvie INC. | $676.96 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $422.48 | 2022-2025 | Saphnelo |
| Ucb, INC. | $406.50 | 2022-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $370.39 | 2022-2025 | Taltz |
| Glaxosmithkline, LLC. | $256.23 | 2022-2025 | Benlysta |
| Ani Pharmaceuticals, INC. | $255.65 | 2022-2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $110.37 | 2022-2025 | |
| Radius Health, INC. | $102.15 | 2022-2025 | Tymlos |
| Genzyme Corporation | $89.91 | 2023-2024 | |
| Aurinia Pharma U.S., INC. | $86.28 | 2023-2025 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $71.61 | 2024-2025 | Orencia |
| Genentech USA, INC. | $64.44 | 2023-2025 | Actemra, Gazyva |
| Fresenius Kabi USA, LLC | $43.10 | 2023-2024 | Idacio |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $40.23 | 2023-2024 | Hyrimoz |
| Kiniksa Pharmaceuticals International, Plc | $33.08 | 2024 | Arcalyst |
| Kyowa Kirin, INC. | $29.81 | 2024 | Crysvita |
| Alexion Pharmaceuticals, INC. | $29.53 | 2024 | |
| Pfizer INC. | $26.78 | 2023 | |
| Alvogen INC | $19.15 | 2023 | Teriparatide |
| Tonix Medicines, INC. | $18.26 | 2025 | Tonmya |
| Almatica Pharma LLC | $17.71 | 2025 | Teriparatide |
| Mylan Institutional INC. | $17.15 | 2023 | Fulphila |
| Mallinckrodt Hospital Products INC. | $13.98 | 2025 | Acthar |
| Organon LLC | $12.75 | 2023 | Renflexis, Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lu Hine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.